Immuron Limited (IMRN) shares gained 2.61% in after-hours on Wednesday, January 12, 2022, and closed the daily trading at $3.93. Even in the regular trading session, IMRN’s stock soared 46.18%. The stock volume remained 45.23 million shares. IMRN shares have fallen 53.29% over the last 12 months, and they have moved up 30.72% in the past week. Over the past three months, the stock has gained 3.51%, while over the past six months, it has declined 39.87%.
Let’s discuss its recent news and developments
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
>> 7 Top Picks for the Post-Pandemic Economy <<
IMRN new research agreement
On January 12, 2022, Immuron Limited (IMRN) announced the funding of a new research agreement with the U.S Department of Defense.
Read More
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
The new agreement is based on a therapeutic Bovine Immunoglobulin supplement targeting Travelers’ Diarrhea caused by Enterotoxigenic Escherichia Coli (ETEC), is aimed at testing and confirming the efficacy of a single larger dose regimen of Travelan® in a controlled human infection model (CHIM) clinical study using the enterotoxigenic Escherichia coli (ETEC) strain H10407.
In the clinical study, 60 volunteers will be enrolled from military populations and will be randomly assigned to receive either a once-daily dose of 1200 mg of Travelan or a placebo.
IMRN update on the clinical trial of Travelan
On November 15, 2021, Immuron Limited (IMRN), provided an update to its shareholders and the market on the planned clinical trial program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC products in Travelers’ Diarrhea sponsored by the Uniformed Services University of the Health Sciences (USU).
USU is expecting to commence enrolling in April 2022 for the planned clinical trial and is hoping to complete enrollment in approximately 18 months. USU already has started manufacturing to produce the first batches of investigational medical products for the clinical trial program.
The trial is a randomized, double-blind, placebo-controlled multicenter clinical trial designed to evaluate the effectiveness of 3 commercially available nutraceuticals: A prebiotic (Bimuno®), a probiotic (Florastor®), and IMM-124E (Travelan®)
Conclusion
Immuron stock skyrocketed on Wednesday after the recent funding for its research agreement with the U.S Department of Defense. We can expect it to continue its momentum on Thursday as well.
>> 7 Top Picks for the Post-Pandemic Economy <<
About the company
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Travelan® is a listed medicine in Australia and Canada whereas, in the U.S., it is sold as a dietary supplement for digestive tract protection.
